Sol-Gel Technologies Ltd.SLGL
Price (close)
$60.74
Market cap
$169.2M
P/E
—
Revenue (FY)
$19.4M
Net income
-$6.1M
Dividend yield
—
1-year total return
117.0%
Net margin
-31.6%
Revenue growth
68.0%
Debt / equity
—
What Sol-Gel Technologies Ltd. does.
approaches to develop pioneering treatments for patients with severe skin conditions, with a successful track record of two NDA approvals
and a pipeline of product candidates being developed for orphan indications. We successfully developed pioneer topical drugs Twyneo and
Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients,
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.8M | $31.3M | $3.9M | $1.6M | $11.5M | $19.4M |
| Net income | -$29.3M | $3.2M | -$14.9M | -$27.2M | -$10.6M | -$6.1M |
| Free cash flow | -$25.7M | -$7.8M | -$9.7M | -$17.9M | -$13.9M | $275,000 |
More on SLGL.
- Sol-Gel Technologies Ltd. summary
- Sol-Gel Technologies Ltd. financial statements
- Sol-Gel Technologies Ltd. key metrics
- Sol-Gel Technologies Ltd. health scores and style box
- Sol-Gel Technologies Ltd. earnings
- Sol-Gel Technologies Ltd. dividends
- Sol-Gel Technologies Ltd. valuation
- Sol-Gel Technologies Ltd. ownership and insiders
- Sol-Gel Technologies Ltd. peers
Figures from Sol-Gel Technologies Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.